KemPharm Strengthens its Board of Directors as Company Prepares for Multiple Clinical and Business Milestones in 2014

 KemPharm Strengthens its Board of Directors as Company Prepares for Multiple
                   Clinical and Business Milestones in 2014

Richard Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri,
Vice-President - General Counsel for Stine Seed Company, Added to KemPharm's

PR Newswire

CORALVILLE, Iowa, Jan. 13, 2014

CORALVILLE,Iowa, Jan. 13, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical
stage biopharmaceutical company focused on the discovery and development of
new, safer therapies to treat pain, announced today the appointment of Richard
Pascoe, CEO of Apricus Biosciences, and Joseph B. Saluri, Vice-President -
General Counsel, Stine Seed Company, to the company's Board of Directors. The
additions of Mr. Pascoe and Mr. Saluri bring extensive public company and
business development experience to KemPharm as the company prepares for
multiple clinical and business milestones in 2014, including the expected
submission of a New Drug Application (NDA) for KP201, KemPharm's lead clinical
candidate, in the third quarter of 2014.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "2014 is
expected to be a pivotal year for KemPharm as we target a third-quarter NDA
submission for KP201 and seek to advance several of our high-value
abuse-deterrent prodrugs through the clinic. The appointments of Richard and
Joseph to our Board bring highly relevant experience and expertise to KemPharm
that should help us to fully capitalize on the numerous opportunities that we
foresee both in terms of business growth and development potential."

Richard Pascoe is currently the Chief Executive Officer of Apricus Biosciences
(NASDAQ: APRI), a position that he has held since March of 2013. Prior to
Apricus, Mr. Pascoe was the Chief Executive Officer of Somaxon Pharmaceuticals
where he was responsible for the FDA approval and commercialization of its
lead drug Silenor^® prior to the merger of Somaxon with Pernix Therapeutics.
Mr. Pascoe's career is further highlighted by a series of senior management
roles at ARIAD Pharmaceuticals, Inc., King Pharmaceuticals, Inc., Medco
Research, Inc. (which was acquired by King), COR Therapeutics, Inc., B. Braun
Interventional and The BOC Group. Mr. Pascoe served as a Commissioned Officer
with the U.S. Army 24th Infantry Division, following his graduation from the
United States Military Academy at West Point where he received a B.S degree in

Mr. Pascoe remarked, "I greatly welcome the opportunity to join KemPharm's
Board as the company embarks on what I believe will be a momentous 2014. Not
only does KP201 offer the potential to re-define the prescription opioid
market given its ability to limit abuse and opioid-induced constipation, but
KemPharm is also poised to advance several other candidates that could further
reshape the pain and ADHD markets. Travis and his team have built a
tremendous company, and I look forward to being instrumental in its continued

Joseph Saluri currently holds the position of Vice President and General
Counsel for Stine Seed Company and is also a member of the Board of Directors
for NewLink Genetics. An employee of Stine Seed Company since 1999, Mr.
Saluri has held positions of increasing authority at the company and is
presently responsible for establishing collaborative licensing, research, and
marketing alliances with international biotechnology and agribusiness
companies, in addition to managing the legal and intellectual property affairs
for the Stine Companies. Previous to his employment with Stine, Mr. Saluri was
an attorney and solicitor at law with Nicholas Critelli Associates, PC, in Des
Moines, IA and London. Mr. Saluri received a BS/BA from Drake University and
a JD from Drake University Law School.

Mr. Saluri commented, "Given my Iowa roots, I'm very excited to be a part of
KemPharm's Board and have the opportunity to be a part of another Iowa life
sciences success story. In particular, KemPharm's highly differentiated
pipeline and proprietary LAT platform offer the company numerous growth
options, and I am eager to work with Travis and his team to maximize its full

About KemPharm
KemPharm is a biopharmaceutical company focused on the discovery and
development of new chemical entities (NCEs) to treat serious medical
conditions through its proprietary and broadly applicable Ligand Activated
Therapy (LAT) approach. The company utilizes its LAT technology to generate
improved prodrug versions of FDA approved drugs in the high needs areas of
pain, ADHD and other CNS diseases. KemPharm's lead clinical candidate, KP201,
is in development for the treatment of acute, moderate to moderately severe
pain with a new drug application (NDA) expected to be filed in the third
quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201
offers unique physicochemical and pharmacological attributes that may deliver
additional patient benefits, including reduced potential for abuse and
reduction or elimination of opioid-induced constipation (OIC). KemPharm's
pipeline is also highlighted by KP511, its hydromorphone prodrug for pain,
KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate
for the treatment of ADHD. For more information on KemPharm, please visit the
company's website at

For KemPharm, Inc: Media / Investor Contacts:
Christal Mickle    Jason Rando / Joshua Drumm, Ph.D.
319-665-2575       Tiberend Strategic Advisors, Inc.  212.827.0020


SOURCE KemPharm, Inc.

Press spacebar to pause and continue. Press esc to stop.